Sökning: "Peter Nygren"

Visar resultat 16 - 20 av 21 avhandlingar innehållade orden Peter Nygren.

  1. 16. Individually Tailored Toxicity-based Chemotherapy : Studies on Patients with Primary and Metastatic Breast Cancer

    Författare :Henrik Lindman; Jonas Bergh; Carl Blomqvist; Peter Nygren; Bo Nordenskjöld; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Oncology; breast cancer; tailored chemotherapy; toxicity-based dosing; high-dose therapy; MR imaging; G-CSF; epirubicin; docetaxel; cyclophosphamide; 5-fluorouracil; Onkologi; Oncology; Onkologi;

    Sammanfattning : Standard dosing of chemotherapy based on body surface area (BSA) results in large individual differences in toxicity due to a large inter-patient variability in pharmacokinetics (PK) and pharmacodynamics (PD). This results in under-dosing in certain patients with a potentially weaker antitumoral effect. LÄS MER

  3. 17. Cellular Pharmacology of the Novel Antitumoural Cyanoguanidine CHS 828

    Författare :Henrik Lövborg; Rolf Larsson; Peter Nygren; Klas Wiman; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacology; CHS 828; Cyanoguanidines; Oncology; Pharmacology; Farmakologi; Pharmacological research; Farmakologisk forskning;

    Sammanfattning : The antitumoural cyanoguanidine CHS 828 has shown promising activity in a number of preclinical and clinical studies. However, the mechanisms underlying the cell death induced by CHS 828 has not been clarified. This thesis describes in vitro studies of the cellular pharmacology of CHS 828. LÄS MER

  4. 18. New Methods to Screen for Cancer Drugs and to Evaluate their Mechanism of Action

    Författare :Linda Rickardson; Rolf Larsson; Peter Nygren; Henrik Lövborg; Kjell Grankvist; Uppsala universitet; []
    Nyckelord :Pharmacology; Cancer drugs; Screening; Gene expression; Farmakologi;

    Sammanfattning : Cancer is a common disease and due to problems with resistance against cancer drugs and the limited benefit from chemotherapy in many diagnoses, there is a need to develop new cancer drugs. In this thesis new methods to screen for cancer drugs and to evaluate their mechanism of action are discussed. LÄS MER

  5. 19. High-throughput screening using multicellular tumor spheroids to reveal and exploit tumor-specific vulnerabilities

    Författare :Wojciech Senkowski; Mårten Fryknäs; Rolf Larsson; Peter Nygren; Mats Gustafsson; Krister Wennerberg; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; spheroids; high-throughput screening; nitazoxanide; OXPHOS; gene expression profiling; statins; drug repositioning; 3D cell culture; quiescent cells; Medical Science; Medicinsk vetenskap;

    Sammanfattning : High-throughput drug screening (HTS) in live cells is often a vital part of the preclinical anticancer drug discovery process. So far, two-dimensional (2D) monolayer cell cultures have been the most prevalent model in HTS endeavors. However, 2D cell cultures often fail to recapitulate the complex microenvironments of in vivo tumors. LÄS MER

  7. 20. Exploring Cancer Drugs In Vitro and In Vivo : With Special Reference to Chemosensitivity Testing and Early Clinical Development

    Författare :Anne von Heideman; Peter Nygren; Bengt Tholander; Rolf Larsson; Seija Grénman; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; cytotoxic drug; in vitro assay; drug development; phase I clinical trial; Oncology; Onkologi; Oncology; Onkologi;

    Sammanfattning : The aims of this thesis were to investigate the utility of in vitro drug sensitivity testing to optimize the use of cancer chemotherapy and to assess the properties of a new cancer drug in a phase I clinical trial. Tumour cells from patients were analysed with the short-term Fluorometric Microculture Cytotoxicity Assay (FMCA). LÄS MER